Perez Algorta, Guillermo http://orcid.org/0000-0001-6610-4951
MacPherson, Heather A.
Arnold, L. Eugene
Hinshaw, Stephen P.
Hechtman, Lily
Sibley, Margaret H.
Owens, Elizabeth B.
Funding for this research was provided by:
National Institute of Mental Health (U01 MH50461, U01 MH50477, U01MH50440, U01 MH50467, U01 MH50453)
Article History
Received: 18 June 2019
Accepted: 11 December 2019
First Online: 20 December 2019
Compliance with ethical standards
:
: Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks), has consulted with Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire. Dr. Sibley has consulted with Takeda. Dr. Hechtman has received research support, served on advisory boards, and been a speaker for Ortho-Janssen, Purdue, Shire, and Ironshore, and received book royalties from Guilford, APA, John Hopkins, and Oxford University Press. Drs. Perez Algorta, MacPherson, Hinshaw and Owens report no biomedical financial interests or potential conflict of interest.